Valuation : Crinetics Pharmaceuticals

Market Cap 9.01B 7.75B 7.28B 6.66B 12.42B 852B 12.52B 86.06B 33.52B 435B 33.84B 33.1B 1,402B P/E 2026 *
-18.5x
P/E 2027 * -20.6x
Enterprise Value 8B 6.89B 6.46B 5.91B 11.04B 757B 11.12B 76.46B 29.78B 387B 30.06B 29.4B 1,245B EV / Sales 2026 *
49.5x
EV / Sales 2027 * 46.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week+0.13%
1 month+1.71%
3 months+160.50%
6 months+108.82%
Current year+82.49%
1 week 84.84
Extreme 84.84
85.01
1 month 83.75
Extreme 83.75
85.01
Current year 32.3
Extreme 32.3
85.01
1 year 32.3
Extreme 32.3
85.01
3 years 15.76
Extreme 15.76
85.01
5 years 15.23
Extreme 15.23
85.01
10 years 10.63
Extreme 10.63
85.01
Manager TitleAgeSince
President 57 2026-08-31
Corporate Secretary - 2026-08-31
Director TitleAgeSince
Director/Board Member 57 2026-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Issuer sale

Chief Financial Officer

-209,427 0.1986%
9/1/26 Issuer sale

Founder

-905,240 0.8585%
9/1/26 Issuer sale

Chairman

-232,151 0.2202%

Financials

2026 *2027 *
Net sales 162M 139M 131M 120M 223M 15.3B 225M 1.55B 602M 7.82B 608M 595M 25.18B 180M 154M 145M 133M 248M 16.97B 250M 1.71B 668M 8.67B 674M 660M 27.94B
Net income -447M -385M -361M -330M -617M -42.28B -622M -4.27B -1.66B -21.61B -1.68B -1.64B -69.59B -470M -405M -380M -347M -648M -44.46B -654M -4.49B -1.75B -22.72B -1.77B -1.73B -73.18B
Net Debt -1.01B -865M -812M -743M -1.39B -95.04B -1.4B -9.6B -3.74B -48.57B -3.78B -3.69B -156B -647M -557M -522M -478M -892M -61.16B -899M -6.18B -2.41B -31.26B -2.43B -2.38B -101B
Logo Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Sector
-
Date Price Change Volume
26-08-31 US$84.95 +0.13% 8,208,422
26-08-28 US$84.84 -0.01% 1,127,886
26-08-27 US$84.85 +0.01% 1,058,995
26-08-26 US$84.84 -0.02% 479,524
26-08-25 US$84.86 +0.09% 1,241,641
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CRNX Stock